ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2022
Successful Use of Lanadelumab in an Older Patient With Type II Hereditary Angioedema.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType II hereditary angioedema (HAE) is a rare, genetic disorder characterized by recurring subcutaneous and/or submucosal edema throughout the body and causes significant morbidity and mortality. Lanadelumab is a novel, long-term prophylactic treatment option for HAE and has proven to be an effective treatment option. However, data are limited in patients with type II HAE or aged ≥ 65 years. We present a case of HAE treated with lanadelumab in a patient of an underrepresented population. CASE PRESENTATION: An 81-year-old male patient was diagnosed with type II HAE at the age of 75 years. Initially, he described having attacks of abdominal pain weekly that could last up to several days. At age 77 years, he began an on-demand treatment, icatibant, which diminished pain. However, after increasing frequency of attacks, the patient started receiving lanadelumab 300 mg subcutaneously every 2 weeks. He went from requiring on-demand treatment 2 to 3 times per month to once in 6 months.
conclusionsLong-term prophylaxis is critical for managing HAE patients, but data are limited for patients with type II HAE and aged ≥ 65 years. Our case supports the use of lanadelumab in these populations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.